Dr. Clarke on Melanoma Biopsies

Video

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

There are approximately 1.5 million biopsies performed in the United States each year for atypical moles, Clarke says. These biopsies are done to exclude the possibility of melanoma, though about 15% are difficult to diagnose.

The myPath test, developed by Myriad Genetics, is an objective 23-gene signature assay that helps in the differentiation of malignant melanoma and a benign nevus.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD